Lupin receives USFDA approval for its generic version of Tolvaptan tablets, indicated for autosomal dominant polycystic ...

Besides this common manifestation, however, the renal ciliopathies present with profoundly different phenotypes, resulting in either polycystic kidney disease (PKD) or nephronophthisis (NPH) ...

A physical therapist was shocked to learn that for her, some of her crucial organs had an expiration date. With proactive ...

WILLIAMSBURG — This time last year, Langdon Richardson and his family were in the final weeks of preparation for a double ...

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

Pharma major Lupin Ltd on Thursday said it has  received approval from the US health regulator for its generic version of ...

Mumbai: Global pharma major, Lupin Limited, has received approval from the United States Food and Drug Administration (U.S.

A study of real-world patients with ADPKD supports tolvaptan’s role in slowing annual eGFR decline. Treatment with tolvaptan modestly but significantly attenuates long-term decline of kidney ...

Crinetics Pharmaceuticals Inc. has disclosed somatostatin receptor type 3 (SSTR3) agonists reported to be useful for the treatment of autosomal dominant polycystic kidney disease.